Recently, Forbes released the 2023 Asia's Top 200 Small and Medium-sized Listed Companies list, 59 Chinese companies including 30 mainland companies were on the list, and Jiudian Pharmaceuticals and Yanjin Puzi became the representatives of Hunan enterprises among them.

This year’s annual Asia’s Best Under A Billion list recognizes 200 small and midsized publicly traded companies in the region that outperformed despite stiff global headwinds like inflation and rising funding costs.

In 2022, JiuDian Pharmaceutical's revenue increased by 42.92% year-on-year, net profit increased by 32.05% year-on-year, and the compounded growth rate of revenue in the past three years exceeded 30%. Against the backdrop of a downturn in which the Shenzhen Composite Index, GEM Index, SSE 50 Index, Sci-Tech 50 Index, and Shenwan Pharmaceutical Index all fell by nearly 20% throughout the year, the company's stock price maintained a steady upward trend in FY2022, with an EPS of RMB0.82, a year-on-year increase of 32.26%. The series of data reflects the resilience and strong momentum of Jiudian Pharmaceutical's development, and also lays a solid foundation for the company to be on the list this time.